Eucrates Biomedical Acquisition Corp. Unit
EUCRU
EUCRU was delisted on the 26th of April, 2023.
19 hedge funds and large institutions have $18.4M invested in Eucrates Biomedical Acquisition Corp. Unit in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
36% more funds holding
Funds holding: 14 → 19 (+5)
32% less capital invested
Capital invested by funds: $27.1M → $18.4M (-$8.7M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIM
Cowen Investment Management
New York
|
+$992K |
| 2 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$785K |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$785K |
| 4 |
SC
Sculptor Capital
New York
|
+$785K |
| 5 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$750K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.29M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$4.99M |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$436K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$100K |
| 5 |
CS
Clear Street
New York
|
-$90K |
EUCRU Hedge Fund Activity: Q1 2022 in Review
19 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q1 2022, worth a combined $18.4M — down 32% from $27.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new EUCRU positions and 5 closed out — a net gain of 5 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Cowen Investment Management, opening a new position worth an estimated $992K. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $7.29M sold.
- 19 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q1 2022, up from 14 in Q4 2021.
- Funds reported $18.4M of Eucrates Biomedical Acquisition Corp. Unit stock for Q1 2022, down 32% quarter-over-quarter.
- 10 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q1 2022 and 5 closed out, a net change of +5 holders.
- The largest Eucrates Biomedical Acquisition Corp. Unit buyer in Q1 2022 was Cowen Investment Management, an estimated $992K added.
- The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q1 2022 was T. Rowe Price Associates, an estimated $7.29M sold.
Based on aggregated 13F filings for Q1 2022.